LMR Partners’s United Therapeutics UTHR Stock Holding History

LMR Partners’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$19M	Sell	32,000 -12,700	-28%	-$6.32M	0.04%	226
2025 Q4	$21.8M	Sell	44,700 -356,300	-89%	-$166M	0.04%	190
2025 Q3	$168M	Buy	+401,000	New	+$135M	0.74%	17
2025 Q2	–	Sell	-5,000	Closed	-$1.54M	–	1662
2025 Q1	$1.54M	Sell	5,000 -5,000	-50%	-$1.71M	0.01%	705
2024 Q4	$3.53M	Sell	10,000 -24,600	-71%	-$9.04M	0.03%	470
2024 Q3	$12.4M	Buy	34,600 +4,600	+15%	+$1.55M	0.1%	176
2024 Q2	$9.56M	Sell	30,000 -16,400	-35%	-$4.34M	0.08%	216
2024 Q1	$10.7M	Hold	46,400	–	–	0.11%	175
2023 Q4	$10.2M	Buy	+46,400	New	+$10.7M	0.12%	197

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

LMR Partners's UTHR Position: Q1 2026 in Review

LMR Partners increased its United Therapeutics (UTHR) stake by 7.1% in Q1 2026, buying an estimated $542K and bringing the position to 16,436 shares worth $9.75M. The position accounts for 0.02% of the portfolio, ranked #445.

LMR Partners first reported a position in UTHR in Q1 2015 and has held it in 7 quarters since. 850 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

LMR Partners held 16,436 shares of United Therapeutics worth $9.75M as of Q1 2026.
LMR Partners bought 1,089 United Therapeutics shares in Q1 2026, an estimated $542K.
United Therapeutics made up 0.02% of LMR Partners's portfolio in Q1 2026, its #445 holding.
LMR Partners first reported a position in United Therapeutics in Q1 2015 and has held it in 7 quarters since.
850 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on LMR Partners's 13F filing for Q1 2026, filed 15 May 2026.